Cargando…

Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery

Detalles Bibliográficos
Autores principales:	Katanaev, Vladimir L., Valnohova, Jana, Silachev, Denis N., Larasati, Yonika A., Koval, Alexey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328272/ https://www.ncbi.nlm.nih.gov/pubmed/37056130 http://dx.doi.org/10.4103/1673-5374.369106

Ejemplares similares

Restoration of the GTPase activity and cellular interactions of Gα(o) mutants by Zn(2+) in GNAO1 encephalopathy models
por: Larasati, Yonika A., et al.
Publicado: (2022)

Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R
por: Larasati, Yonika A., et al.
Publicado: (2023)

Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation
por: Silachev, Denis, et al.
Publicado: (2022)

Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease
por: Solis, Gonzalo P., et al.
Publicado: (2021)

Gαo (GNAO1) encephalopathies: plasma membrane vs. Golgi functions
por: Solis, Gonzalo P., et al.
Publicado: (2017)

Humanization of Drosophila Gαo to Model GNAO1 Paediatric Encephalopathies
por: Savitsky, Mikhail, et al.
Publicado: (2020)

Phenotypes in children with GNAO1 encephalopathy in China
por: Li, Yanmei, et al.
Publicado: (2023)

Visual Function in Children with GNAO1-Related Encephalopathy
por: Gambardella, Maria Luigia, et al.
Publicado: (2023)

GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome
por: Danti, Federica Rachele, et al.
Publicado: (2017)

Marine Natural Products from the Russian Pacific as Sources of Drugs for Neurodegenerative Diseases
por: Khotimchenko, Yuri S., et al.
Publicado: (2022)

GNAO1 encephalopathy: further delineation of a severe neurodevelopmental syndrome affecting females
por: Marcé-Grau, Anna, et al.
Publicado: (2016)

Spectrum of movement disorders in GNAO1 encephalopathy: in-depth phenotyping and case-by-case analysis
por: Kim, Soo Yeon, et al.
Publicado: (2020)

Gain-of-function mutation in Gnao1: A murine model of epileptiform encephalopathy (EIEE17)?
por: Kehrl, Jason M., et al.
Publicado: (2014)

A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers
por: Ahmed, Kamal, et al.
Publicado: (2016)

The future of molecular dynamics simulations in drug discovery
por: Borhani, David W., et al.
Publicado: (2011)

Dramatic dysbalancing of the Wnt pathway in breast cancers
por: Koval, Alexey, et al.
Publicado: (2018)

The Chemopreventive Activity of Indonesia Medicinal Plants Targeting on Hallmarks of Cancer
por: Meiyanto, Edy, et al.
Publicado: (2019)

Highlighting the Dystonic Phenotype Related to GNAO1
por: Wirth, Thomas, et al.
Publicado: (2022)

Beyond TNBC: Repositioning of Clofazimine Against a Broad Range of Wnt-Dependent Cancers
por: Xu, Jiabin, et al.
Publicado: (2020)

Improved approaches to channel capacity estimation discover compromised GPCR signaling in diverse cancer cells
por: Koval, Alexey, et al.
Publicado: (2023)

Phenotypes of GNAO1 Variants in a Chinese Cohort
por: Yang, Xiaoling, et al.
Publicado: (2021)

Local and substrate-specific S-palmitoylation determines subcellular localization of Gαo
por: Solis, Gonzalo P., et al.
Publicado: (2022)

Paramagnetic NMR in drug discovery
por: Softley, Charlotte A., et al.
Publicado: (2020)

Identification of Novel Elements of the Drosophila Blisterome Sheds Light on Potential Pathological Mechanisms of Several Human Diseases
por: Bilousov, Oleksii, et al.
Publicado: (2014)

The Anticancer Drug Discovery Potential of Marine Invertebrates from Russian Pacific
por: Katanaev, Vladimir L., et al.
Publicado: (2019)

Open drug discovery in Alzheimer's disease
por: Axtman, Alison D., et al.
Publicado: (2023)

The pK(a) Distribution of Drugs: Application to Drug Discovery
por: Manallack, David T.
Publicado: (2007)

Curcumin Analog Pentagamavunon-1 (PGV-1) Sensitizes Widr Cells to 5-Fluorouracil through Inhibition of NF-κB Activation
por: Meiyanto, Edy, et al.
Publicado: (2018)

The down-regulation of GNAO1 and its promoting role in hepatocellular carcinoma
por: Pei, Xiaoyu, et al.
Publicado: (2013)

GNAO1-related neurodevelopmental disorder: Literature review and caregiver survey
por: JoJo Yang, Qian-Zhou, et al.
Publicado: (2022)

NMR in target driven drug discovery: why not?
por: Keiffer, Sébastien, et al.
Publicado: (2020)

Evolving paradigms for natural-product drug discovery
por: Cordell, Geoffrey A
Publicado: (2022)

Computational drug discovery under RNA times
por: Bernetti, Mattia, et al.
Publicado: (2022)

Scurvy: A treatable forgotten fatal differential diagnosis and potential etiology of leukemia and aplastic anemia in pediatric population
por: Mashauri, Harold L.
Publicado: (2023)

Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
por: Boudou, Cédric, et al.
Publicado: (2022)

An expanding role for cell biologists in drug discovery and pharmacology
por: Sorger, Peter K., et al.
Publicado: (2012)

Key drivers of biomedical innovation in cancer drug discovery
por: Huber, Margit A, et al.
Publicado: (2015)

Drug discovery and development: Role of basic biological research
por: Mohs, Richard C., et al.
Publicado: (2017)

Applications of machine learning in computer-aided drug discovery
por: Turzo, SM Bargeen Alam, et al.
Publicado: (2022)

Molecular Biology and Evolution of Cancer: From Discovery to Action
por: Somarelli, Jason A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pj5nikr0eem7l6t1op0me2td1s